• Australasian Genetic Counselors’ Perceptions of Their Role in Supporting Clients’ Behavior Change.
    • Jacobs C, Turbitt E, McEwen A, Atkins L.
    • J Pers Med. 2022 Dec 23;13(1):30. doi: 10.3390/jpm13010030.
    • A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.
    • Torr B, Jones C, Choi S, Allen S, Kavanaugh G, Hamill M, Garrett A, MacMahon S, Loong L, Reay A, Yuan L, Valganon Petrizan M, Monson K, Perry N, Fallowfield L, Jenkins V, Gold R, Taylor A, Gabe R, Wiggins J, Lucassen A, Manchanda R, Gandhi A, George A, Hubank M, Kemp Z, Evans DG, Bremner S, Turnbull C.
    • J Med Genet. 2022 Dec;59(12):1179-1188. doi: 10.1136/jmg-2022-108655. Epub 2022 Jul 22.

    •• Trial registration number: ISRCTN87845055: BRCA-DIRECT- Is digitally delivered information about genetic testing feasible, effective and acceptable to women with breast cancer?. (ISRCTN registry)

    •• Press: UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer. (GenomeWeb)

    • Investigating the presentation of uncertainty in an icon array: A randomized trial.
    • Recchia G, Lawrence ACE, Freeman ALJ.
    • PEC Innov. 2022 Dec;1:None. doi: 10.1016/j.pecinn.2021.100003.
    • UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer.
    • [No author given]
    • GenomeWeb. The Scan. 2022 Nov 23.

    •• Original research:

    A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot.

    • Development of a web-based, theory-guided narrative intervention for women at elevated risk for breast cancer.
    • Katz ML, Senter L, Reiter PL, Emerson B, Ennis AC, Shane-Carson KP, Aeilts A, Cassingham HR, Schnell PM, Agnese DM, Toland AE, Sweet K.
    • Patient Educ Couns. 2022 Oct 29:S0738-3991(22)00820-5. doi: 10.1016/j.pec.2022.10.348. Epub ahead of print.
    • Use of a chatbot to increase uptake of cascade genetic testing.
    • Schmidlen T, Jones CL, Campbell-Salome G, McCormick CZ, Vanenkevort E, Sturm AC.
    • J Genet Couns. 2022 Oct;31(5):1219-1230. doi: 10.1002/jgc4.1592. Epub 2022 May 26.
    • Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients.
    • Butow P, Napier C, Campbell R, Bartley N, Best M, Ballinger ML.
    • Patient Educ Couns. 2022 Oct;105(10):3110-3115. doi: 10.1016/j.pec.2022.06.009. Epub 2022 Jun 16.
    • Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort.
    • Senter L, Veney D, Surplus T, Haynam M, Adams EJ, Hampel H, Toland AE, Presley CJ, Padamsee TJ, Lee CN, Hovick SR, Stover DG.
    • JCO Oncol Pract. 2022 Sep 21:OP2200316. doi: 10.1200/OP.22.00316. Epub ahead of print.
    • Mainstream genetic testing for women with ovarian cancer provides a solid basis for patients to make a well-informed decision about genetic testing.
    • Bokkers K, Bleiker EMA, Hoogendam JP, Velthuizen ME, Schreuder HWR, Gerestein CG, Lange JG, Louwers JA, Koudijs MJ, Ausems MGEM, Zweemer RP.
    • Hered Cancer Clin Pract. 2022 Sep 8;20(1):33. doi: 10.1186/s13053-022-00238-w.
    • Experience with a nurse-driven genetic counseling pathway of Italian women with uninformative BRCA test result.
    • Blondeaux E, Lambertini M, Buzzatti G, Bruzzone C, Baraga M, Pisani R, Del Mastro L, Pronzato P, Varesco L, Bonelli L.
    • J Genet Couns. 2022 Aug 29. doi: 10.1002/jgc4.1630. Epub ahead of print.
    • How do women who are informed that they are at increased risk of breast cancer appraise their risk? A systematic review of qualitative research.
    • Woof VG, Howell A, McWilliams L, Gareth Evans D, French DP.
    • Br J Cancer. 2022 Aug 24. doi: 10.1038/s41416-022-01944-x. Epub ahead of print.
    • Further validation of the Perceptions of Uncertainties in Genome Sequencing scale among patients with cancer undergoing tumor sequencing.
    • Umstead KL, Campbell R, Napier CE, Bartley N, Best MC, Butow PN, Biesecker BB.
    • Clin Genet. 2022 Aug;102(2):110-116. doi: 10.1111/cge.14169. Epub 2022 Jun 10.
    • Making BRCA1 genetic test reports easier to understand through user-centered design: A randomized trial.
    • Recchia G, Lawrence ACE, Capacchione L, Freeman ALJ.
    • Genet Med. 2022 Aug;24(8):1684-1696. doi: 10.1016/j.gim.2022.04.016. Epub 2022 May 6.
    • Experiences of individuals with a variant of uncertain significance on genetic testing for hereditary cancer risks: a mixed method systematic review.
    • Gould D, Walker R, Makari-Judson G, Seven M.
    • J Community Genet. 2022 Aug;13(4):371-379. doi: 10.1007/s12687-022-00600-4. Epub 2022 Jul 12.
    • Cancer patients' understandings of genetic variants of uncertain significance in clinical care.
    • Amano Y, Raz A, Timmermans S, Shkedi-Rafid S.
    • J Community Genet. 2022 Aug;13(4):381-388. doi: 10.1007/s12687-022-00594-z. Epub 2022 May 26.
    • Comparing the attitudes of physicians and non-physicians toward communicating a patient's BRCA1 mutation to a first-degree relative against a patient's wishes.
    • Zebrack JE, Yang W, Milone M, Coppes MJ.
    • J Community Genet. 2022 Aug;13(4):403-410. doi: 10.1007/s12687-022-00591-2. Epub 2022 May 21.
    • Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2.
    • McCormick S, Hicks S, Wooters M, Grant C.
    • J Genet Couns. 2022 Aug;31(4):956-964. doi: 10.1002/jgc4.1568. Epub 2022 Mar 4.
    • The Communication Chain of Genetic Risk: Analyses of Narrative Data Exploring Proband–Provider and Proband–Family Communication in Hereditary Breast and Ovarian Cancer.
    • Pedrazzani C, Aceti M, Schweighoffer R, Kaiser-Grolimund A, Bürki N, Chappuis PO, Graffeo R, Monnerat C, Pagani O, Rabaglio M, Katapodi MC, Caiata-Zufferey M.
    • J Pers Med. 2022 Jul 29;12(8):1249. doi: 10.3390/jpm12081249.
    • A qualitative study of unaffected ATM and CHEK2 carriers: How participants make meaning of 'moderate risk' genetic results in a population breast cancer screening trial.
    • James JE, Riddle L, Caruncho M, Koenig BA, Joseph G.
    • J Genet Couns. 2022 Jul 25. doi: 10.1002/jgc4.1617. Epub ahead of print.
    • Precise, Genotype-First Breast Cancer Prevention: Experience With Transferring Monogenic Findings From a Population Biobank to the Clinical Setting.
    • Jürgens H, Roht L, Leitsalu L, Nõukas M, Palover M, Nikopensius T, Reigo A, Kals M, Kallak K, Kütner R, Budrikas K, Kuusk S, Valvere V, Laidre P, Toome K, Rekker K, Tooming M, Ülle Murumets, Kahre T, Kruuv-Käo K, Õunap K, Padrik P, Metspalu A, Esko T, Fischer K, Tõnisson N.
    • Front Genet. 2022 Jul 22;13:881100. doi: 10.3389/fgene.2022.881100.
    • Insight into how patients with prostate cancer interpret and communicate genetic test results: implications for families.
    • Leader AE, Mercado J, Klein A, Hyatt C, Gross L, Brandt R, Giri VN.
    • J Community Genet. 2022 Jul 22. doi: 10.1007/s12687-022-00603-1. Epub ahead of print.
    • Patient and Clinician Decision Support to Increase Genetic Counseling for Hereditary Breast and Ovarian Cancer Syndrome in Primary Care: A Cluster Randomized Clinical Trial.
    • Kukafka R, Pan S, Silverman T, Zhang T, Chung WK, Terry MB, Fleck E, Younge RG, Trivedi MS, McGuinness JE, He T, Dimond J, Crew KD.
    • JAMA Netw Open. 2022 Jul 18;5(7):e2222092. doi: 10.1001/jamanetworkopen.2022.22092.

    Identifier: NCT03470402: Decision Support for BRCA Testing in Ethnically Diverse Women. (ClinicalTrials.gov)

    • The Clinical and Psychosocial Outcomes for Women Who Received Unexpected Clinically Actionable Germline Information Identified through Research: An Exploratory Sequential Mixed-Methods Comparative Study.
    • Forrest LE, Forbes Shepherd R, Tutty E, Pearce A, Campbell I, Devereux L, Trainer AH, James PA, Young MA.
    • J Pers Med. 2022 Jul 7;12(7):1112. doi: 10.3390/jpm12071112.
    • Genetic clinicians' confidence in BOADICEA comprehensive breast cancer risk estimates and counselees' psychosocial outcomes: a prospective study.
    • Brédart A, De Pauw A, Tüchler A, Lakeman IMM, Anota A, Rhiem K, Schmutzler R, van Asperen CJ, Devilee P, Stoppa-Lyonnet D, Kop JL, Dolbeault S.
    • Clin Genet. 2022 Jul;102(1):30-39. doi: 10.1111/cge.14147. Epub 2022 May 16.
    • Validation of the Knowledge of Genome Sequencing (KOGS) scale in cancer patients.
    • Butow P, Napier C, Campbell R, Bartley N, Best M, Ballinger ML.
    • Patient Educ Couns. 2022 Jun 16:S0738-3991(22)00287-7. doi: 10.1016/j.pec.2022.06.009. Epub ahead of print.
    • Healthcare Predictors of Information Dissemination About Genetic Risks.
    • Henderson V, Strayhorn SM, Bergeron NQ, Strahan DC, Ganschow PS, Khanna AS, Watson K, Hoskins K, Molina Y.
    • Cancer Control. 2022 Jan-Dec [First Published 2022 Jun 6];29:10732748221104666. doi: 10.1177/10732748221104666.
    • Population-based BRCA1/2 testing programmes are highly acceptable in the Jewish community: results of the JeneScreen Study.
    • Tiller JM, Cousens NE, Kaur R, Rowley S, Ko YA, Mahale S, Bankier A, Meiser B, Barlow-Stewart K, Burnett L, Jacobs C, James P, Trainer A, Neil S, Campbell IG, Andrews L, Delatycki M.
    • J Med Genet. 2022 Jun 3:jmedgenet-2022-108519. doi: 10.1136/jmedgenet-2022-108519. Epub ahead of print.
    • Laboratory-related outcomes from integrating an accessible delivery model for hereditary cancer risk assessment and genetic testing in populations with barriers to access.
    • Amendola LM, Shuster E, Leo MC, Dorschner MO, Rolf BA, Shirts BH, Gilmore MJ, Okuyama S, Zepp JM, Kauffman TL, Mittendorf KF, Bellcross C, Jenkins CL, Joseph G, Riddle L, Syngal S, Ukaegbu C, Goddard KAB, Wilfond BS, Jarvik GP; CHARM Study.
    • Genet Med. 2022 Jun;24(6):1196-1205. doi: 10.1016/j.gim.2022.02.006. Epub 2022 Mar 16.
    • Medical knowledge and information needs among women with pathogenic variants in moderate-risk genes for hereditary breast cancer attending genetic counseling at an academic hospital in Germany-A qualitative approach.
    • Stracke C, Lemmen C, Rhiem K, Schmutzler R, Kautz-Freimuth S, Stock S.
    • J Genet Couns. 2022 Jun;31(3):698-712. doi: 10.1002/jgc4.1536. Epub 2021 Nov 26.
    • Patient Experience with a Gynecologic Oncology-Initiated Genetic Testing Model for Women with Tubo-Ovarian Cancer.
    • Sadinsky MB, Power J, Ambrosio E, Palma L, Zeng X, Foulkes WD, Weber E.
    • Curr Oncol. 2022 May 15;29(5):3565-3575. doi: 10.3390/curroncol29050288.
    • Testing a best practices risk result format to communicate genetic risks.
    • Davis KW, Roter DL, Schmidlen T, Scheinfeldt LB, Klein WMP.
    • Patient Educ Couns. 2021 May;104(5):936-943. doi: 10.1016/j.pec.2020.10.021. Epub 2020 Oct 19.
    • How patients deal with an ambiguous medical test: Decision-making after genetic testing.
    • Scherr CL, Ramesh S, Getachew-Smith H, Kalke K, Ramsey K, Fischhoff B, Vadaparampil ST.
    • Patient Educ Couns. 2021 May;104(5):953-959. doi: 10.1016/j.pec.2020.10.020. Epub 2020 Oct 18.
    • Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis.
    • Kritzik R, Usoro E, Peshkin BN, Isaacs C, Valdimarsdottir HB, Willey S, O'Neill S, DeMarco T, Nusbaum R, Jandorf L, Kelleher S, Schwartz MD.
    • Psychooncology. 2022 May;31(5):788-797. doi: 10.1002/pon.5863. Epub 2021 Dec 18.
    • Incomplete Penetrance of Population-Based Genetic Screening Results in Electronic Health Record.
    • Elhanan G, Kiser D, Neveux I, Dabe S, Bolze A, Metcalf WJ, Lu JT, Grzymski JJ.
    • Front Genet. 2022 Apr 27;13:866169. doi: 10.3389/fgene.2022.866169.
    • Reflex BRCA1 and BRCA2 tumour genetic testing for high-grade serous ovarian cancer: streamlined for clinicians but what do patients think?
    • McCuaig JM, Ferguson SE, Vicus D, Ott K, Stockley TL, Kim RH, Metcalfe KA.
    • Hered Cancer Clin Pract. 2022 Apr 13;20(1):15. doi: 10.1186/s13053-022-00221-5.
    • "I wish that there was more info": characterizing the uncertainty experienced by carriers of pathogenic ATM and/or CHEK2 variants.
    • Reyes KG, Clark C, Gerhart M, Newson AJ, Ormond KE.
    • Fam Cancer. 2022 Apr;21(2):143-155. doi: 10.1007/s10689-021-00251-3. Epub 2021 Apr 15.
    • Large-scale group genetic counseling: Evaluation of a novel service delivery model in a Canadian hereditary cancer clinic.
    • Lohn Z, Fok A, Richardson M, Derocher H, Mung SW, Nuk J, Yuson J, Jevon M, A Schrader K, Sun S.
    • J Genet Couns. 2022 Apr;31(2):459-469. doi: 10.1002/jgc4.1512. Epub 2021 Oct 1.
    • Psychosocial outcome and health behaviour intent of breast cancer patients with BRCA1/2 and PALB2 pathogenic variants unselected by a priori risk.
    • Padmanabhan H, Hassan NT, Wong SW, Lee YQ, Lim J, Hasan SN, Yip CH, Teo SH, Thong MK, Mohd Taib NA, Yoon SY.
    • PLoS One. 2022 Feb 15;17(2):e0263675. doi: 10.1371/journal.pone.0263675.
    • Characteristics and experiences of patients from a community-based and consumer-directed hereditary cancer population screening initiative.
    • Greve V, Odom K, Pudner S, Lamb NE, Cooper SJ, East K.
    • HGG Adv. 2021 Aug 24 [eCollection 2022 Jan 13];3(1):100055. doi: 10.1016/j.xhgg.2021.100055.
    • Genetic Literacy and Communication of Genetic Information in Families Concerned with Hereditary Breast and Ovarian Cancer: A Cross-Study Comparison in Two Countries and within a Timeframe of More Than 10 Years.
    • Pedrazzani C, Ming C, Bürki N, Caiata-Zufferey M, Chappuis PO, Duquette D, Heinimann K, Heinzelmann-Schwarz V, Graffeo-Galbiati R, Merajver SD, Milliron KJ, Monnerat C, Pagani O, Rabaglio M, Katapodi MC.
    • Cancers (Basel). 2021 Dec 13;13(24):6254. doi: 10.3390/cancers13246254.
    • Information needs on breast cancer genetic and non-genetic risk factors in relatives of women with a BRCA1/2 or PALB2 pathogenic variant.
    • Brédart A, De Pauw A, Anota A, Tüchler A, Dick J, Müller A, Kop JL, Rhiem K, Schmutzler R, Devilee P, Stoppa-Lyonnet D, Dolbeault S.
    • Breast. 2021 Dec;60:38-44. doi: 10.1016/j.breast.2021.08.011. Epub 2021 Aug 23.
    • Implication and Influence of Multigene Panel Testing with Genetic Counseling in Korean Patients with BRCA1/2 Mutation-Negative Breast Cancer.
    • Park JS, Shin S, Lee YJ, Lee ST, Nam EJ, Han JW, Lee SH, Kim TI, Park HS.
    • Cancer Res Treat. 2021 Nov 17. doi: 10.4143/crt.2021.978. Epub ahead of print.
    • Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomes.
    • Binion S, Sorgen LJ, Peshkin BN, Valdimarsdottir H, Isaacs C, Nusbaum R, Graves KD, DeMarco T, Wood M, McKinnon W, Garber J, McCormick S, Ladd MK, Schwartz MD.
    • J Telemed Telecare. 2021 Nov 15:1357633X211052220. doi: 10.1177/1357633X211052220. Epub ahead of print.
    • Challenges and Errors in Genetic Testing: The Fifth Case Series.
    • Farmer MB, Bonadies DC, Pederson HJ, Mraz KA, Whatley JW, Darnes DR, Denton JJ, De Rosa D, Heatherly A, Kenney J, Lane K, Paul D, Pelletier RC, Shannon K, Williams D, Matloff ET.
    • Cancer J. 2021 Nov-Dec 01;27(6):417-422. doi: 10.1097/PPO.0000000000000553.
    • Case series
    • Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients.
    • Hur YM, Mun J, Kim MK, Lee M, Kim YH, Kim SC.
    • J Korean Med Sci. 2021 Oct 4;36(38):e241. doi: 10.3346/jkms.2021.36.e241.
    • Genetic counseling clinical documentation: Practice Resource of the National Society of Genetic Counselors.
    • Hunt Brendish K, Patel D, Yu K, Alexander CK, Lemons J, Gunter A, Carmany EP.
    • J Genet Couns. 2021 Oct;30(5):1336-1353. doi: 10.1002/jgc4.1491. Epub 2021 Aug 14.
    • Alternative Genetic Counseling Approach Leads to Higher Patient Satisfaction, Study Suggests.
    • Curtin C.
    • GenomeWeb. Research & Discovery. 2021 Sep 27.
    • Pretest Genetic Education Video Versus Genetic Counseling for Men Considering Prostate Cancer Germline Testing: A Patient-Choice Study to Address Urgent Practice Needs.
    • Russo J, McDougall C, Bowler N, Shimada A, Gross L, Hyatt C, Kelly WK, Calvaresi A, Handley NR, Hirsch IH, Izes JK, Lallas CD, Mann M, Mark JR, Mille PJ, Preate D Jr, Trabulsi EJ, Tsang M, Chandrasekar T, Weiner PR, Gomella LG, Giri VN.
    • JCO Precis Oncol. 2021 Sep 1;5:PO.21.00238. doi: 10.1200/PO.21.00238.

    Research news: Men Give Thumbs Up to Video on Genetic Testing in Prostate Cancer. (Medscape Oncology)

    • Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    • Metcalfe KA, Eisen A, Poll A, Candib A, McCready D, Cil T, Wright F, Demsky R, Mancuso T, Sun P, Narod SA.
    • Ann Surg Oncol. 2021 Sep;28(9):4967-4973. doi: 10.1245/s10434-021-09855-6. Epub 2021 Mar 24.

    Commentary:

    Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy.

    • Patient-Reported Outcomes following Genetic Testing for Familial Hypercholesterolemia, Breast and Ovarian Cancer Syndrome, and Lynch Syndrome: A Systematic Review.
    • Hendricks-Sturrup RM, Joseph L, Lu CY.
    • J Pers Med. 2021 Aug 27;11(9):850. doi: 10.3390/jpm11090850.
    • Community research collaboration to develop a promotores-based hereditary breast cancer education program for Spanish-speaking Latinas.
    • Almeida R, Lopez-Macha A, Dugatkin T, Joseph G, Duron Y, Hurtado de Mendoza A, D Graves K, Fejerman L.
    • Health Educ Res. 2021 Jun 11:cyab011. doi: 10.1093/her/cyab011. Epub ahead of print.
    • GeneLiFT: A novel test to facilitate rapid screening of genetic literacy in a diverse population undergoing genetic testing.
    • Milo Rasouly H, Cuneo N, Marasa M, DeMaria N, Chatterjee D, Thompson JJ, Fasel DA, Wynn J, Chung WK, Appelbaum P, Weng C, Bakken S, Gharavi AG.
    • J Genet Couns. 2021 Jun;30(3):742-754. doi: 10.1002/jgc4.1364. Epub 2020 Dec 26.
    • A Collaborative Model to Implement Flexible, Accessible and Efficient Oncogenetic Services for Hereditary Breast and Ovarian Cancer: The C-MOnGene Study.
    • Lapointe J, Dorval M, Chiquette J, Joly Y, Guertin JR, Laberge M, Gekas J, Hébert J, Pomey MP, Cruz-Marino T, Touhami O, Blanchet Saint-Pierre A, Gagnon S, Bouchard K, Rhéaume J, Boisvert K, Brousseau C, Castonguay L, Fortier S, Gosselin I, Lachapelle P, Lavoie S, Poirier B, Renaud MC, Ruizmangas MG, Sebastianelli A, Roy S, Côté M, Racine MM, Roy MC, Côté N, Brisson C, Charette N, Faucher V, Leblanc J, Dubeau MÈ, Plante M, Desbiens C, Beaumont M, Simard J, Nabi H.
    • Cancers (Basel). 2021 May 31;13(11):2729. doi: 10.3390/cancers13112729.
    • The role of the genetic testing industry in patient education of hereditary cancer: An observational study assessing the quality of patient education videos.
    • Greenberg DC, Kamara D, Tatsugawa Z, Mendoza M, Pineda E, Holschneider CH, Zakhour M.
    • Gynecol Oncol. 2021 May;161(2):516-520. doi: 10.1016/j.ygyno.2021.02.013. Epub 2021 Feb 19.
    • A Comparison of Patient-Reported Outcomes Following Consent for Genetic Testing Using an Oncologist- or Genetic Counselor-Mediated Model of Care.
    • McCuaig JM, Thain E, Malcolmson J, Keshavarzi S, Armel SR, Kim RH.
    • Curr Oncol. 2021 Apr 8;28(2):1459-1471. doi: 10.3390/curroncol28020138.
    • Videoconferencing to deliver genetics services: a systematic review of telegenetics in light of the COVID-19 pandemic.
    • Brown EG, Watts I, Beales ER, Maudhoo A, Hayward J, Sheridan E, Rafi I.
    • Genet Med. 2021 Apr 6. doi: 10.1038/s41436-021-01149-2. Epub ahead of print.
    • Psychosocial Interventions for Women with a BRCA1 or BRCA2 Mutation: A Scoping Review.
    • Boghosian T, McCuaig JM, Carlsson L, Metcalfe KA.
    • Cancers (Basel). 2021 Mar 24;13(7):1486. doi: 10.3390/cancers13071486.
    • Variations in breast cancer surgical treatment and timing: determinants and disparities.
    • Dankwa-Mullan I, George J, Roebuck MC, Tkacz J, Willis VC, Reyes F, Arriaga YE.
    • Breast Cancer Res Treat. 2021 Mar 10. doi: 10.1007/s10549-021-06155-1. Epub ahead of print.
    • The Knowledge and Attitude of Patients Diagnosed with Epithelial Ovarian Cancer towards Genetic Testing.
    • Shin W, Jeong G, Son Y, Seo SS, Kang S, Park SY, Lim MC.
    • Int J Environ Res Public Health. 2021 Feb 26;18(5):2312. doi: 10.3390/ijerph18052312.
    • Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.
    • Koptiuch C, Espinel WF, Kohlmann WK, Zhao J, Kaphingst KA.
    • JCO Precis Oncol. 2021 Jan 19;5:PO.20.00199. doi: 10.1200/PO.20.00199.
    • Influence of lived experience on risk perception among women who received a breast cancer polygenic risk score: 'Another piece of the pie'.
    • Willis AM, Smith SK, Meiser B, James PA, Ballinger ML, Thomas DM, Yanes T, Young MA.
    • J Genet Couns. 2021 Jan 19. doi: 10.1002/jgc4.1384. Epub ahead of print.
    • Misinterpretation of Hereditary Breast Cancer Risk and Its Association with Information Sharing Motives among Women at Low Likelihood of Carrying a BRCA1/2 Mutation.
    • Zhao J, McBride CM, Guan Y.
    • Public Health Genomics. 2020 [Jan 2021];23(5-6):252-256. doi: 10.1159/000511131. Epub 2020 Oct 27.
    • Understanding of Inheritance and Genetic Variation Assessed through the Use of an Engaging Real-Life Survey.
    • Ephrem E, Gleason E, Maurer K, Sullivan KE.
    • Public Health Genomics. 2020 Dec 8:1-6. doi: 10.1159/000512086. Epub ahead of print.
    • Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer.
    • [No author given]
    • FORCE. XRAY. 2020 Oct 26.

    Original research:

    Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.

    • Experiences and attitudes of hereditary cancer screening patients in a consumer directed testing model.
    • Greve V, Garner M, Odom K, Cooper SJ, East KM.
    • Patient Educ Couns. 2020 Oct 11:S0738-3991(20)305498. doi: 10.1016/j.pec.2020.10.014. Epub ahead of print.
    • Telehealth for genetic counseling: A systematic evidence review.
    • Danylchuk NR, Cook L, Shane-Carson KP, Cacioppo CN, Hardy MW, Nusbaum R, Steelman SC, Malinowski J.
    • J Genet Couns. 2021 Oct;30(5):1361-1378. doi: 10.1002/jgc4.1481. Epub 2021 Aug 6.
    • Review
    • A pilot randomized trial of an educational intervention to increase genetic counseling and genetic testing among Latina breast cancer survivors.
    • Conley CC, Castro-Figueroa EM, Moreno L, Dutil J, García JD, Burgos C, Ricker C, Kim J, Graves KD, Ashing KT, Quinn GP, Soliman H, Vadaparampil ST.
    • J Genet Couns. 2020 Sep 16. doi: 10.1002/jgc4.1324. Epub ahead of print.
    • Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes in Women With Breast Cancer.
    • Hadar T, Mor P, Amit G, Lieberman S, Gekhtman D, Rabinovitch R, Levy-Lahad E.
    • JAMA Oncol. 2020 Sep 1;6(9):1460-1463. doi: 10.1001/jamaoncol.2020.2059.

    Research news: Study Sees Survival Boost For BRCA1/2 Carriers Tested Before Breast Cancer Diagnosis. (GenomeWeb)

    Research news: 'Knowledge Is Power': Knowing BRCA1/2 Status Tied to Survival. (Medscape)

    Research news: Knowing about an inherited BRCA mutation improves outcomes for women with breast cancer. (FORCE. XRAY.)

    • Informing models of cancer genetic care in the era of multigene panel testing with patient-led recommendations.
    • Underhill-Blazey M, Blonquist T, Chittenden A, Pozzar R, Nayak M, Lansang K, Hong F, Garber J, Stopfer JE.
    • J Genet Couns. 2020 Aug 26. doi: 10.1002/jgc4.1317. Epub ahead of print.
    • Using patient perspectives to inform communication training materials for health care professionals discussing BRCA mutation testing.
    • Shilling V, Catt S, Jenkins V, Fallowfield L.
    • Breast Cancer Res Treat. 2020 Aug 18. doi: 10.1007/s10549-020-05871-4. Epub ahead of print.
    • Benefits and limitations of telegenetics: A literature review.
    • Gorrie A, Gold J, Cameron C, Krause M, Kincaid H.
    • J Genet Couns. 2021 Aug;30(4):924-937. doi: 10.1002/jgc4.1418. Epub 2021 Apr 4.
    • Review
    • A Modern Dilemma: How Experts Grapple with Ambiguous Genetic Test Results.
    • Scherr CL, Ross Arguedas AA, Getachew-Smith H, Marshall-Fricker C, Shrestha N, Brooks K, Fischhoff B, Vadaparampil ST.
    • Med Decis Making. 2020 Jul;40(5):655-668. doi: 10.1177/0272989X20935864.
    • Women's responses and understanding of polygenic breast cancer risk information.
    • Yanes T, Kaur R, Meiser B, Scheepers-Joynt M, McInerny S, Barlow-Stewart K, Antill Y, Salmon L, Smyth C, James PA, Young MA.
    • Fam Cancer. 2020 May 20. doi: 10.1007/s10689-020-00185-2. Epub ahead of print.
    • Patient perspectives on variant reclassification after cancer susceptibility testing.
    • Halverson CME, Connors LM, Wessinger BC, Clayton EW, Wiesner GL.
    • Mol Genet Genomic Med. 2020 Apr 24:e1275. doi: 10.1002/mgg3.1275. [Epub ahead of print]
    • Mainstream consent programs for genetic counseling in cancer patients: A systematic review.
    • Scheinberg T, Young A, Woo H, Goodwin A, Mahon KL, Horvath LG.
    • Asia Pac J Clin Oncol. 2020 Apr 20. doi: 10.1111/ajco.13334. [Epub ahead of print]
    • Longitudinal outcomes with cancer multigene panel testing in previously tested BRCA1/2 negative patients.
    • Bradbury AR, Egleston BL, Patrick-Miller LJ, Rustgi N, Brandt A, Brower J, DiGiovanni L, Fetzer D, Berkelbach C, Long JM, Powers J, Stopfer JE, Domchek SM.
    • Clin Genet. 2020 Apr;97(4):601-609. doi: 10.1111/cge.13716.
    • The impact of communicating uncertain test results in cancer genetic counseling: A systematic mixed studies review.
    • Medendorp NM, van Maarschalkerweerd PEA, Murugesu L, Daams JG, Smets EMA, Hillen MA.
    • Patient Educ Couns. 2020 Mar 19. pii: S0738-3991(20)30149-X. doi: 10.1016/j.pec.2020.03.015. [Epub ahead of print]
    • Updated Guideline Moves Genetic Testing Beyond BRCA.
    • Narozniak R.
    • OncologyLive. 2020 Mar 13;21(6).
    • News

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Do Preferred Risk Formats Lead to Better Understanding? A Multicenter Controlled Trial on Communicating Familial Breast Cancer Risks Using Different Risk Formats.
    • Henneman L, van Asperen CJ, Oosterwijk JC, Menko FH, Claassen L, Timmermans DR.
    • Patient Prefer Adherence. 2020 Feb 19;14:333-342. doi: 10.2147/PPA.S232941. eCollection 2020.
    • Disparities in BRCA counseling across providers in a diverse population of young breast cancer survivors.
    • Reid S, Cragun D, Tezak A, Weidner A, Moore J, Mayer IA, Shu XO, Ye F, Fan R, Vadaparampil S, Pal T.
    • Genet Med. 2020 Feb 18. doi: 10.1038/s41436-020-0762-0. [Epub ahead of print]
    • Experts say more women should be tested for BRCA1 and BRCA2 genetic mutations.
    • Printz C.
    • Cancer. 2020 Feb 15;126(4):693. doi: 10.1002/cncr.32723.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Referencing BRCA in hereditary cancer risk discussions: In search of an anchor in a sea of uncertainty.
    • Waltz M, Prince AER, O'Daniel JM, Foreman AKM, Powell BC, Berg JS.
    • J Genet Couns. 2020 Jan 22. doi: 10.1002/jgc4.1219. [Epub ahead of print]
    • Patients with pathogenic variants for breast cancer other than BRCA1 and BRCA2: qualitative interviews about health care experiences.
    • Clift KE, Macklin SK, Hines SL.
    • Hered Cancer Clin Pract. 2019 Dec 16;17:32. doi: 10.1186/s13053-019-0132-6. eCollection 2019.
    • Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
    • Vysotskaia V, Kaseniit KE, Bucheit L, Ready K, Price K, Johansen Taber K.
    • Cancer. 2019 Nov 4. doi: 10.1002/cncr.32572. [Epub ahead of print]
    • Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer.
    • Scott D, Friedman S, Telli ML, Kurian AW.
    • J Oncol Pract. 2019 Oct 15:JOP1900221. doi: 10.1200/JOP.19.00221. [Epub ahead of print]
    • Do Women who Receive a Negative BRCA1/2 Risk Result Understand the Implications for Breast Cancer Risk?
    • Guan Y, Condit CM, Escoffery C, Bellcross CA, McBride CM.
    • Public Health Genomics. 2019 Oct 9:1-8. doi: 10.1159/000503129. [Epub ahead of print]
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
    • Rayes N, Bowen DJ, Coffin T, Nebgen D, Peterson C, Munsell MF, Gavin K, Lechner R, Crase J, Polinsky D, Romero I, Blank SV, Levine DA, Norquist BM, Swisher EM, Lu KH.
    • BMC Cancer. 2019 Jul 2;19(1):648. doi: 10.1186/s12885-019-5868-x.
    • Adverse Events in Genetic Testing: The Fourth Case Series.
    • Farmer MB, Bonadies DC, Mahon SM, Baker MJ, Ghate SM, Munro C, Nagaraj CB, Besser AG, Bui K, Csuy CM, Kirkpatrick B, McCarty AJ, McQuaid SW, Sebastian J, Sternen DL, Walsh LK, Matloff ET.
    • Cancer J. 2019 Jul/Aug;25(4):231-236. doi: 10.1097/PPO.0000000000000391.
    • Case series
    • Accuracy in risk understanding among BRCA1/2-mutation carriers.
    • Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F.
    • Patient Educ Couns. 2019 May 5. pii: S0738-3991(18)30887-5. doi: 10.1016/j.pec.2019.05.007. [Epub ahead of print]
    • A narrative overview of the patients' outcomes after multigene cancer panel testing, and a thorough evaluation of its implications for genetic counselling.
    • Esteban I, Lopez-Fernandez A, Balmaña J.
    • Eur J Med Genet. 2019 May;62(5):342-349. doi: 10.1016/j.ejmg.2018.11.027. Epub 2018 Nov 23.
    • Review
    • Development and testing of the KnowGene scale to assess general cancer genetic knowledge related to multigene panel testing.
    • Underhill-Blazey M, Stopfer J, Chittenden A, Nayak MM, Lansang K, Lederman R, Garber J, Gundersen DA.
    • Patient Educ Couns. 2019 Apr 13. pii: S0738-3991(19)30138-7. doi: 10.1016/j.pec.2019.04.014. [Epub ahead of print]
    • Communication about genetic testing with breast and ovarian cancer patients: a scoping review.
    • Jacobs C, Patch C, Michie S.
    • Eur J Hum Genet. 2019 Apr;27(4):511-524. doi: 10.1038/s41431-018-0310-4. Epub 2018 Dec 20.
    • Uncertainty related to multigene panel testing for cancer: a qualitative study on counsellors' and counselees' views.
    • Medendorp NM, Hillen MA, Murugesu L, Aalfs CM, Stiggelbout AM, Smets EMA.
    • J Community Genet. 2019 Apr;10(2):303-312. doi: 10.1007/s12687-018-0393-1. Epub 2018 Nov 14.
    • Experiences and interpretations of BRCA1/2 testing among women affected by breast or ovarian cancer who received a negative result.
    • Stafford L, Flehr A, Judd F, Lindeman GJ, Gibson P, Komiti A, Mann GB, Kentwell M.
    • J Community Genet. 2019 Mar 27. doi: 10.1007/s12687-019-00415-w. [Epub ahead of print]
    • Impact of Implementing B-RSTTM to Screen for Hereditary Breast and Ovarian Cancer on Risk Perception and Genetic Counseling Uptake Among Women in an Academic Safety Net Hospital.
    • Wernke K, Bellcross C, Gabram S, Ali N, Stanislaw C.
    • Clin Breast Cancer. 2019 Mar 11. pii: S1526-8209(18)30730-4. doi: 10.1016/j.clbc.2019.02.014. [Epub ahead of print]
    • Cancer communication research in the era of genomics and precision medicine: a scoping review.
    • Kaphingst KA, Peterson E, Zhao J, Gaysynsky A, Elrick A, Hong SJ, Krakow M, Pokharel M, Ratcliff CL, Klein WMP, Khoury MJ, Chou WS.
    • Genet Med. 2018 Dec 21. doi: 10.1038/s41436-018-0402-0. [Epub ahead of print]
    • Review
    • Use and Patient-Reported Outcomes of Clinical Multigene Panel Testing for Cancer Susceptibility in the Multicenter Communication of Genetic Test Results by Telephone Study.
    • Hall MJ, Patrick-Miller LJ, Egleston BL, Domchek SM, Daly MB, Ganschow P, Grana G, Olopade OI, Fetzer D, Brandt A, Chambers R, Clark DF, Forman A, Gaber R, Gulden C, Horte J, Long JM, Lucas T, Madaan S, Mattie K, McKenna D, Montgomery S, Nielsen S, Powers J, Rainey K, Rybak C, Savage M, Seelaus C, Stoll J, Stopfer JE, Yao XS, Bradbury AR.
    • JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00199. Epub 2018 Dec 18.
    • Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge.
    • Machirori M, Patch C, Metcalfe A.
    • Eur J Med Genet. 2018 Dec 12. pii: S1769-7212(18)30405-1. doi: 10.1016/j.ejmg.2018.12.006. [Epub ahead of print]
    • A Systematic Review of the Psychological Implications of Genetic Testing: A Comparative Analysis Among Cardiovascular, Neurodegenerative and Cancer Diseases.
    • Oliveri S, Ferrari F, Manfrinati A, Pravettoni G.
    • Front Genet. 2018 Dec 10;9:624. doi: 10.3389/fgene.2018.00624.
    • A narrative overview of the patients’ outcomes after multigene cancer panel testing: Thorough evaluation of its implications for genetic counselling.
    • Estebana I, Lopez-Fernandez A, Balmaña J.
    • Eur J Med Genet. 2018 Nov 23. pii: S1769-7212(18)30422-1. doi: 10.1016/j.ejmg.2018.11.027. [Epub ahead of print]
    • Review, Comment
    • Next-Generation Service Delivery: A Scoping Review of Patient Outcomes Associated with Alternative Models of Genetic Counseling and Genetic Testing for Hereditary Cancer.
    • McCuaig JM, Armel SR, Care M, Volenik A, Kim RH, Metcalfe KA.
    • Cancers (Basel). 2018 Nov 13;10(11). pii: E435. doi: 10.3390/cancers10110435.
    • Predictors of risk-reducing surgery intentions following genetic counseling for hereditary breast and ovarian cancer.
    • Ladd MK, Peshkin BN, Senter L, Baldinger S, Isaacs C, Segal H, Philip S, Phillips C, Shane K, Martin A, Weinstein V, Pilarski R, Jeter J, Sweet K, Hatten B, Wurtmann EJ, Phippen S, Bro D, Schwartz MD.
    • Transl Behav Med. 2018 Nov 10. doi: 10.1093/tbm/iby101. [Epub ahead of print]
    • MAGENTA Study Aims to Find Best Genetic Counseling Method for Online Cancer Risk Testing.
    • Ray T.
    • Precision Oncology News. Disease Areas. Cancer. 2018 Aug 4.
    • Research news

    Identifier: NCT02993068: Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible). (ClinicalTrials.gov)

    • Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
    • Tea MM, Tan YY, Staudigl C, Eibl B, Renz R, Asseryanis E, Berger A, Pfeiler G, Singer CF.
    • PLoS One. 2018 Jul 12;13(7):e0200559. doi: 10.1371/journal.pone.0200559. eCollection 2018.
    • Patients' Views of Treatment-Focused Genetic Testing (TFGT): Some Lessons for the Mainstreaming of BRCA1 and BRCA2 Testing.
    • Wright S, Porteous M, Stirling D, Lawton J, Young O, Gourley C, Hallowell N.
    • J Genet Couns. 2018 May 11. doi: 10.1007/s10897-018-0261-5. [Epub ahead of print]
    • Communicating with Daughters About Familial Risk of Breast Cancer: Individual, Family, and Provider Influences on Women's Knowledge of Cancer Risk.
    • Peipins LA, Rodriguez JL, Hawkins NA, Soman A, White MC, Hodgson ME, DeRoo LA, Sandler DP.
    • J Womens Health (Larchmt). 2018 May;27(5):630-639. doi: 10.1089/jwh.2017.6528. Epub 2018 Jan 29.
    • Examination of the Patient-Focused Impact of Cancer Telegenetics Among a Rural Population: Comparison with Traditional In-Person Services.
    • Solomons NM, Lamb AE, Lucas FL, McDonald EF, Miesfeldt S.
    • Telemed J E Health. 2018 Feb;24(2):130-138. doi: 10.1089/tmj.2017.0073. Epub 2017 Jul 21.
    • Family Communication, Risk Perception and Cancer Knowledge of Young Adults from BRCA1/2 Families: a Systematic Review.
    • Young AL, Butow PN, Vetsch J, Quinn VF, Patenaude AF, Tucker KM, Wakefield CE.
    • J Genet Couns. 2017 Dec;26(6):1179-1196. doi: 10.1007/s10897-017-0125-4. Epub 2017 Jun 30.
    • Review
    • Assessment of Current Genetic Counselor Practices in Post-Visit Written Communications to Patients.
    • VandenBoom E, Trepanier AM,Carmany EP.
    • J Genet Couns. 2017 Oct 12. doi: 10.100/s10897-017-0163-y. [Epub ahead of print]
    • Effect on perceived control and psychological distress of genetic knowledge in women with breast cancer receiving a BRCA1/2 test result.
    • Brédart A, Kop JL, De Pauw A, Caron O, Fajac A, Noguès C, Stoppa-Lyonnet D, Dolbeault S.
    • Breast. 2017 Feb;31:121-127. doi: 10.1016/j.breast.2016.10.024. Epub 2016 Nov 9.
    • Long-term experiences with genetic consultation in people with hereditary breast and ovarian cancer.
    • Eismann S, Vetter L, Keller M, Bruckner T, Golatta M, Hennings A, Domschke C, Dikow N, Sohn C, Heil J, Schott S.
    • Arch Gynecol Obstet. 2016 Nov;294(5):1011-1018. Epub 2016 Jun 10.
    • Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer.
    • Jacobs AS, Schwartz MD, Valdimarsdottir H, Nusbaum RH, Hooker GW, DeMarco TA, Heinzmann JE, McKinnon W, McCormick SR, Davis C, Forman AD, Lebensohn AP, Dalton E, Tully DM, Graves KD, Similuk M, Kelly S, Peshkin BN.
    • Fam Cancer. 2016 Oct;15(4):529-39. doi: 10.1007/s10689-016-9900-x.
    • Quality of Life and Psychological State in Chinese Breast Cancer Patients Who Received BRCA1/2 Genetic Testing.
    • Qiu J, Guan J, Yang X, Wu J, Liu G, Di G, Chen C, Hou Y, Han Q, Shen Z, Shao Z, Hu Z.
    • PLoS One. 2016 Jul 18;11(7):e0158531. doi: 10.1371/journal.pone.0158531. eCollection 2016.
    • Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations.
    • Manchanda R, Burnell M, Loggenberg K, Desai R, Wardle J, Sanderson SC, Gessler S, Side L, Balogun N, Kumar A, Dorkins H, Wallis Y, Chapman C, Tomlinson I, Taylor R, Jacobs C, Legood R, Raikou M, McGuire A, Beller U, Menon U, Jacobs I.
    • J Med Genet. 2016 Jul;53(7):472-80. doi: 10.1136/jmedgenet-2015-103740. Epub 2016 Mar 18.
    • The Quality of Genetic Counseling and Connected Factors as Evaluated by Male BRCA1/2 Mutation Carriers in Finland.
    • Kajula O, Kääriäinen M, Moilanen JS, Kyngäs H.
    • J Genet Couns. 2016 Jun;25(3):413-21. doi: 10.1007/s10897-015-9885-x. Epub 2015 Sep 29.
    • BRCA 1/2-negative patients who receive counseling after genetic testing have lower anxiety.
    • Printz C.
    • Cancer. 2016 Apr 15;122(8):1149. doi: 10.1002/cncr.30002.
    • Counselees' Expressed Level of Understanding of the Risk Estimate and Surveillance Recommendation are Not Associated with Breast Cancer Surveillance Adherence.
    • Albada A, van Dulmen S, Dijkstra H, Wieffer I, Witkamp A, Ausems MG.
    • J Genet Couns. 2016 Apr;25(2):279-89. doi: 10.1007/s10897-015-9869-x. Epub 2015 Sep 1.
    • Impact of Genetic Counseling in Women with a Family History of Breast Cancer in Italy.
    • Godino L, Razzaboni E, Bianconi M, Turchetti D.
    • J Genet Couns. 2016 Apr;25(2):405-11. doi: 10.1007/s10897-015-9884-y. Epub 2015 Sep 10.
    • Breast Cancer Survivors' Knowledge of Hereditary Breast and Ovarian Cancer following Genetic Counseling: An Exploration of General and Survivor-Specific Knowledge Items.
    • Scherr CL, Christie J, Vadaparampil ST.
    • Public Health Genomics. [2016 Jan;]19(1):1-10. doi: 10.1159/000439162. Epub 2015 Sep 22.
    • Accuracy of recall of information about a cancer-predisposing BRCA1/2 gene mutation among patients and relatives.
    • Jacobs C, Dancyger C, Smith JA, Michie S.
    • Eur J Hum Genet. 2015 Feb;23(2):147-51. doi: 10.1038/ejhg.2014.84. Epub 2014 May 21.
    • Differences in BRCA counseling and testing practices based on ordering provider type.
    • Cragun D, Camperlengo L, Robinson E, Caldwell M, Kim J, Phelan C, Monteiro AN, Vadaparampil ST, Sellers TA, Pal T.
    • Genet Med. 2015 Jan;17(1):51-57. doi: 10.1038/gim.2014.75. Epub 2014 Jun 12.

    Press: Involving a genetic health care professional may improve quality, reduce unnecessary testing. (Science Daily)

    Press: Survey: Genetic Counseling Leads Some Patients to Cheaper BRCA Tests. (GenomeWeb)

    Blog post: Survey: Genetic Counseling Leads Some Patients to Cheaper BRCA Tests. (Yale Cancer Genetic Counseling)

    • Linking genetic counseling content to short-term outcomes in individuals at elevated breast cancer risk.
    • Kelly KM, Ellington L, Schoenberg N, Agarwal P, Jackson T, Dickinson S, Abraham J, Paskett ED, Leventhal H, Andrykowski M.
    • J Genet Couns. 2014 Oct;23(5):838-48. doi: 10.1007/s10897-014-9705-8. Epub 2014 Mar 28.
    • Understanding of BRCA1/2 genetic tests results: the importance of objective and subjective numeracy.
    • Hanoch Y, Miron-Shatz T, Rolison JJ, Ozanne E.
    • Psychooncology. 2014 Oct;23(10):1142-8. doi: 10.1002/pon.3537. Epub 2014 Apr 14.
    • Lack of shared decision making in cancer screening discussions: results from a national survey.
    • Hoffman RM, Elmore JG, Fairfield KM, Gerstein BS, Levin CA, Pignone MP.
    • Am J Prev Med. 2014 Sep;47(3):251-9. doi: 10.1016/j.amepre.2014.04.011. Epub 2014 Jun 9.
    • Counselee participation in follow-up breast cancer genetic counselling visits and associations with achievement of the preferred role, cognitive outcomes, risk perception alignment and perceived personal control.
    • Albada A, Ausems MG, van Dulmen S.
    • Soc Sci Med. 2014 Sep;116:178-86. doi: 10.1016/j.socscimed.2014.07.012. Epub 2014 Jul 6.
    • Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling.
    • Richter S, Haroun I, Graham TC, Eisen A, Kiss A, Warner E.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii69-viii74. doi: 10.1093/annonc/mdt312.
    • Genetic Counseling, Cancer Screening, Breast Cancer Characteristics, and General Health among a Diverse Population of BRCA Genetic Testers.
    • Beattie MS, Copeland K, Fehniger J, Cheung E, Joseph G, Lee R, Luce J.
    • J Health Care Poor Underserved. [2013 Aug;]24(3):1150-66. doi: 10.1353/hpu.2013.0151.
    • Understanding the Needs of Women Considering Risk-Reducing Salpingo-oophorectomy.
    • Cherry C, Ropka M, Lyle J, Napolitano L, Daly MB.
    • Cancer Nurs. 2013 May-Jun;36(3):E33-8. doi: 10.1097/NCC.0b013e3182642cb5.
    • Theory Development From Studies With Young Women With Breast Cancer Who Are BRCA Mutation Negative.
    • Hamilton R, Kopin S.
    • ANS Adv Nurs Sci. 2013 Apr-Jun;36(2):E41-53. doi: 10.1097/ANS.0b013e3182901ff1.
    • Short-term psychological impact of the BRCA1/2 test result in women with breast cancer according to their perceived probability of genetic predisposition to cancer.
    • Brédart A, Kop JL, Depauw A, Caron O, Sultan S, Leblond D, Fajac A, Buecher B, Gauthier-Villars M, Noguès C, Flahault C, Stoppa-Lyonnet D, Dolbeault S.
    • Br J Cancer. 2013 Mar 19;108(5):1012-20. doi: 10.1038/bjc.2012.599. Epub 2013 Mar 5.
    • Perception of cancer recurrence risk: More information is better.
    • Kelly KM, Ajmera M, Bhattacharjee S, Vohra R, Hobbs G, Chaudhary L, Abraham J, Agnese D.
    • Patient Educ Couns. 2013 Mar;90(3):361-6. doi: 10.1016/j.pec.2011.12.003. Epub 2012 Jan 9.
    • Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing.
    • Francke U, Dijamco C, Kiefer AK, Eriksson N, Moiseff B, Tung JY, Mountain JL.
    • PeerJ. 2013 Feb 12;1:e8. doi: 10.7717/peerj.8. Print 2013.

    Comments on NSGC Discussion Forum

    Subject: Current thoughts on 23andme?

    Press: Consumers have few negative reactions to the results of genetic testing for cancer mutations. (EurekAlert!)

    Press: Get ready for the risks of genetic testing. (CNN)

    • Cognitive and Psychological Impact of BRCA Genetic Counseling in Before and After Definitive Surgery Breast Cancer Patients.
    • Christie J, Quinn GP, Malo T, Lee JH, Zhao X, McIntyre J, Brzosowicz J, Jacobsen PB, Vadaparampil ST.
    • Ann Surg Oncol. 2012 Dec;19(13):4003-11. doi: 10.1245/s10434-012-2460-x. Epub 2012 Jul 6.

    News:

    Pretest genetic counseling informs patients with BRCA mutation.

    Press Release: Pre-Test Genetic Counseling Increases Cancer Knowledge for BRCA Patients (Moffitt Cancer Center)

    • [Perception accuracy of BRCA1/2 mutation predisposition in breast cancer women and associated factors].
    • Leblond D, Brédart A, Dolbeault S, De Pauw A, Stoppa-Lyonnet D, Sultan S.
    • Bull Cancer. 2012 Jun;99(6):673-84.
    • [Article in French]
    • French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing.
    • Maheu C, Apostolidis T, Petri-Cal A, Mouret-Fourme E, Gauthier-Villars M, Lasset C, Berthet P, Fricker JP, Caron O, Luporsi E, Gladieff L, Noguès C, Julian-Reynier C.
    • Fam Cancer. 2012 Jun;11(2):269-78. doi: 10.1007/s10689-012-9512-z.
    • Influence of the family cluster effect on psychosocial variables in families undergoing BRCA1/2 genetic testing for cancer susceptibility.
    • Lapointe J, Abdous B, Camden S, Bouchard K, Goldgar D, Simard J, Dorval M.
    • Psychooncology. 2012 May;21(5):515-23. doi: 10.1002/pon.1936. Epub 2011 Mar 2.
    • Effects of a pre-visit educational website on information recall and needs fulfilment in breast cancer genetic counselling, a randomized controlled trial.
    • Albada A, van Dulmen S, Bensing JM, Ausems MG.
    • Breast Cancer Res. 2012 Mar 6;14(2):R37.

    Retraction:

    Retraction: Effects of a pre-visit educational website on information recall and needs fulfilment in breast cancer genetic counselling, a randomized controlled trial.

    • Permanence of the information given during oncogenetic counseling to persons at familial risk of breast/ovarian and/or colon cancer.
    • Kwiatkowski F, Dessenne P, Laquet C, Petit MF, Bignon YJ.
    • Eur J Hum Genet. 2012 Feb;20(2):141-7. doi: 10.1038/ejhg.2011.169. Epub 2011 Sep 21.
    • Exploring the short-term impact of DNA-testing in breast cancer patients: the counselees' perception matters, but the actual BRCA1/2 result does not.
    • Vos J, Oosterwijk JC, Gomez-Garcia E, Menko FH, Collee MJ, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.
    • Patient Educ Couns. 2012 Feb;86(2):239-51. doi: 10.1016/j.pec.2011.04.017. Epub 2011 Dec 27.